UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 120

Sortiert nach

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

The Journal of clinical investigation, 2014-02, Vol.124 (2), p.499-508

2014

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension

Diabetes care, 2015-03, Vol.38 (3), p.420-428

2015

Link zum Volltext

Verfügbarkeit prüfen

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes

Diabetes care, 2014-07, Vol.37 (7), p.1815-1823

2014

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Diabetes care, 2014-06, Vol.37 (6), p.1650-1659

2014

Link zum Volltext

Verfügbarkeit prüfen

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin

Diabetes care, 2015-03, Vol.38 (3), p.384-393

2015

Link zum Volltext

Verfügbarkeit prüfen

Adipokines and insulin resistance

Molecular medicine (Cambridge, Mass.), 2008-11, Vol.14 (11-12), p.741-751

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

The lancet. Diabetes & endocrinology, 2014-05, Vol.2 (5), p.369-384

2014

Link zum Volltext

Verfügbarkeit prüfen

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Cardiovascular diabetology, 2014-01, Vol.13 (1), p.28-28

2014

Link zum Volltext

Verfügbarkeit prüfen

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Cardiovascular diabetology, 2014-06, Vol.13 (1), p.102-102

2014

Link zum Volltext

Verfügbarkeit prüfen

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

Diabetes & vascular disease research, 2015-03, Vol.12 (2), p.90-100

2015

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet. Diabetes & endocrinology, 2013-11, Vol.1 (3), p.208-219

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

The lancet. Diabetes & endocrinology, 2014-09, Vol.2 (9), p.691-700

2014

Link zum Volltext

Verfügbarkeit prüfen

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

Circulation (New York, N.Y.), 2014-02, Vol.129 (5), p.587-597

2014

Link zum Volltext

Verfügbarkeit prüfen

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

Diabetes care, 2016-10, Vol.39 (10), p.1718-1728

2016

Link zum Volltext

Verfügbarkeit prüfen

Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes

Diabetes care, 2015-03, Vol.38 (3), p.394-402

2015

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Diabetes care, 2013-11, Vol.36 (11), p.3396-3404

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

Diabetes care, 2013-12, Vol.36 (12), p.4015-4021

2013

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

Diabetes care, 2017-02, Vol.40 (2), p.201-209

2017

Link zum Volltext

Verfügbarkeit prüfen

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

Kidney international, 2018-01, Vol.93 (1), p.231-244

2018

Link zum Volltext

Verfügbarkeit prüfen

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Diabetes care, 2014-05, Vol.37 (5), p.1480-1483

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes

Clinical therapeutics, 2016-06, Vol.38 (6), p.1299-1313

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication

Hypertension (Dallas, Tex. 1979), 2016-12, Vol.68 (6), p.1355-1364

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

Cardiovascular diabetology, 2015-01, Vol.14 (1), p.11-11, Article 11

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Clinical therapeutics, 2016-10, Vol.38 (10), p.2265-2276

2016

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Stroke (1970), 2017-05, Vol.48 (5), p.1218-1225

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(119)
Dissertationen
(1)

Sprache

Englisch
(119)
Japanisch
(18)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Humans
(84)
Life Sciences & Biomedicine
(83)
Male
(62)
Female
(60)
Middle Aged
(52)
Endocrinology & Metabolism
(42)
Diabetes Mellitus, Type 2 - Drug Therapy
(39)
Diabetes
(38)
Adult
(35)
Aged
(29)
Benzhydryl Compounds - Therapeutic Use
(27)
Glucosides - Therapeutic Use
(27)
Treatment Outcome
(26)
Double-Blind Method
(25)
Internal Medicine
(25)
Biological And Medical Sciences
(23)
Empagliflozin
(23)
Hypoglycemic Agents - Therapeutic Use
(23)
Cardiovascular System & Cardiology
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin

Adipokines and insulin resistance

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes

Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Suchergebnisse filtern